As KDM5C's function in suppressing type I IFNs and ISGs in breast cancer is apparently dependent on its enzymatic activity, small molecule inhibitors targeting KDM5C enzymatic activity will certainly enhance tumor immunogenicity. The gene discussed is KDM5C; the disease is neoplasm.